EirGenix Inc (台康生技) plans to transfer its listing from the Emerging Stock Board to the Taipei Exchange (TPEX) by the end of next month, chief finance officer Cathy Yang (楊秀權) told a news conference in Taipei yesterday.
The pharmaceutical company, which is a contract development and manufacturing organization (CDMO) and biosimilars maker, started trading its shares on the Emerging Stock Board in November 2016.
It aims to raise NT$600 million (US$19.06 million) through the TPEX debut and would use the proceeds for new drug studies and tests, Yang said.
EirGenix plans to issue 20 million new shares, with the listing price likely set at NT$32, but the final price would depend on the average price on the Emerging Stock Board 30 days before the TPEX listing, Yang added.
It submitted its applications to TPEX in December last year and received approval in March, even though it has yet to turn a profit.
A 2017 recommendation letter from the Industrial Development Bureau (IDB) allowed it to circumvent some listing requirements regarding revenue, earnings and cash flow, the company said.
EirGenix reported net losses of NT$368 million for last year, compared with net losses of NT$175 million in 2017, company data showed.
It plans to spend part of money from the TPEX listing for the phase III clinical trials for its breast cancer drug EG12014, chief executive officer Liu Lee-cheng (劉理成) said.
The drug is a biosimilar of trastuzumab, a monoclonal antibody sold by Swiss pharmaceutical giant Roche Holding AG under the brand name Herceptin, Liu said.
The business potential for EG12014 is huge, as its price would be cheaper than Herceptin, he said, adding that Herceptin’s annual sales last year were 6.98 billion Swiss francs (US$6.94 billion at the current exchange rate).
Herceptin’s patent for Europe expired in 2014, and that for the US is due to expire later this year, which means EG12014 has great potential, he said.
EirGenix has gained regulatory approvals to launch the phase III trials in Taiwan, the US, Georgia, Russia, India and South Korea, and has been meeting with the EU regulator to discuss the trials, Liu said.
“We will invite 800 breast cancer patients to take part in the global clinical trials, and have enrolled 66 so far,” Liu said.
The final-stage trial is expected to be completed in the fourth quarter of next year, or the first quarter in 2021, and the company should gain marketing approvals in 2021 or 2022, he said.
EirGenix last month secured a contract with Sandoz AG to provide the EG12014 for the generic pharmaceuticals division of Swiss giant Novartis AG, Liu said.
The deal would generate US$70 million over next few years, including a US$5 million upfront payment and US$65 million milestone payment, he said.
The headline has been corrected since it was first published.
NOTABLE SHIFT: By 2030, 50% of all laptops would be assembled in Southeast Asia, while Taiwan would still mostly focus on research and development, a report said Global laptop and desktop computer supply chains are expected to shift significantly away from China in the next 10 years, a Market Intelligence & Consulting Institute (MIC, 產業情報研究所) report said. By 2030, only 40 percent of global laptop production would remain in China, said the report, which was released on Thursday. “The reshuffling of the global supply chain will be one of the most important trends in the next 10 years,” the institute said in the report. “In the long run, key component makers will follow laptop assemblers in moving out of China.” The Taipei-based institute predicted most key component makers
Merck Group Taiwan yesterday said that it plans to invest substantially on expanding its fab in Kaohsiung’s Lujhu District (路竹) to better serve its local customers, including Taiwan Semiconductor Manufacturing Co (TSMC, 台積電). The company said it plans to expand its production space by 50 percent in the next five years and its workforce by about 40 percent, Merck Group Taiwan managing director Dick Hsieh (謝志宏) told a media briefing in Taipei. Hsieh declined to disclose investment details, but said that the latest investment would exceed the total amount Merck has invested in Taiwan over the past few years. Those investments would be
Yageo Corp (國巨), the world’s third-largest supplier of multilayer ceramic capacitors, has formed a strategic alliance with Hon Hai Precision Industry Co (鴻海精密) to develop key electronic components for electric vehicles and digital healthcare, it said yesterday. The alliance is to help Yageo boost its revenue from high-end components for vehicles and industrial, medical and aerospace devices, as well as those used in 5G and Internet-of-Things devices, the company said. The companies signed the strategic alliance agreement at Yageo’s headquarters in New Taipei City’s Sindian District (新店). Their cooperation is to start this quarter, the companies said in a joint statement. “Through the cooperation
INVEST IN TAIWAN: A metal components casting firm and the world’s largest maker of aluminum bicycle rims also obtained approvals to join the program Solar Applied Materials Technology Co (SOLAR, 光洋應用材料), a part of Taiwan Semiconductor Manufacturing Co’s (TSMC, 台積電) “green supply chain,” has pledged to invest NT$1 billion (US$34.1 million) to build a new plant at the Tainan Technology Industrial Park (台南科技工業區), the Ministry of Economic Affairs said yesterday. SOLAR has been collaborating with TSMC to extract precious metals from waste and reuse them as “sputtering target” material in high-end semiconductor manufacturing, a TSMC press release issued in May said. Established in 1978, SOLAR also offers key materials and integrated services to customers in the optoelectronics, information and communications technology, petrochemicals and consumer electronics industries,